Organization
Medical Technology Association of Canada (Medtech Canada)
- Meetings this Parliament
- 4
- With MPs
- 1
- Since Nov 2021
- 25
- Active registrations
- 1
Most recent reported meeting: Jul 6, 2026.
Lobbying by Medical Technology Association of Canada (Medtech Canada): its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (organization) In effect since Jan 31, 2025
Filed by Nicole DeKort, President & Chief Executive Officer
Lobbyists
- Mia Spiegelman · Vice President of Regulatory Affairs
- Nicole DeKort · President & CEO
- Raj Malik · Vice-President of Federal Affairs & Health Systems
Institutions they may lobby: Canada Revenue Agency (CRA), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Office of the Commissioner of Lobbying (OCL), Prime Minister's Office (PMO), Public Services and Procurement Canada (PSPC)
What they're lobbying on (8)Hide details
- Medical Device Regulations (SOR/98-282) that require compliance by the medical device technology industry. Addressing issues and providing advice related to Medical Device Regulations in Canada; performance of Therapeutic Products Directorate, Health Canada; other related activities of Health Canada e.g. health protection legislative renewal, cost recovery/user fees, quality systems (ISO 13485), single-use device reuse, Regulatory Review of Drugs and Devices (R2D2). Participate in the legislative/regulatory process with the intent of seeking reasonable approaches based on scientific evidence and changing policies where needed.
- Medical Device Bureau: discussions re. a program that assesses safety, effectiveness and quality of medical devices with respect to the authorization for the sale of medical device technologies in Canada.
- Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada.
- Health Technology Assessment (HTA) - Providing advice and evidence related to the 'Value of Technology' in order to assist in the process of establishing proper medical device funding and reimbursement, contribution to the process of HTA with the intent of seeking reasonable approaches based on scientific evidence and changing reimbursement policies where needed.
- Health Canada - Health Technology Assessment (HTA) and the role of the Canadian Agency for Drugs and Technologies in Health (CADTH), GS1 (Global Standards 1) Canada, Vendor Credentialing, the removal of regulatory barriers to build an innovation economy and provide funding to grow a Canadian Artificial Intelligence & Digital Health cluster that will be globally competitive.
- Environmental regulation of Medical Devices (Canadian Environment Protection Act (CEPA), Chemicals Management Plan, provincial Stewardship regulations), Addressing issues and providing advice related to Medical Devices concerned by these regulations and participation in legislative/regulatory processes with the intent of seeking reasonable approaches based on scientific evidence and revising policies where needed.
- Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.
- Advancing the recommendations made by the Health & Biosciences Economic Strategy Table to grow the medical technology industry in Canada.
Registration 950985-5246-27. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Nicole DeKort · In-house (organization)
- Helena Jaczek · Member of Parliament
Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada. Read more
-
Reported by Nicole DeKort · In-house (organization)
- Shalene Curtis-Micallef · Deputy Minister of Health, Health Canada (HC)
Advancing the recommendations made by the Health & Biosciences Economic Strategy Table to grow the medical technology industry in Canada.
-
Reported by Nicole DeKort · In-house (organization)
- Ritu Banerjee · Interim Head, Innovation, Science and Economic Development Canada (ISED)
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs. Read more
-
Reported by Nicole DeKort · In-house (organization)
- Jade Mallette · Chief of Staff to the Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy and Deputy Chief of Staff, Health Canada (HC)
Advancing the recommendations made by the Health & Biosciences Economic Strategy Table to grow the medical technology industry in Canada.
-
Reported by Nicole DeKort · In-house (organization)
- Lesley Sherban · Chief of Staff to the Minister, Global Affairs Canada (GAC)
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs. Read more
-
Reported by Nicole DeKort · In-house (organization)
- Bruce Randall · Director General, Health Canada (HC)
Medical Device Bureau: discussions re. a program that assesses safety, effectiveness and quality of medical devices with respect to the authorization for the sale of medical device technologies in Canada. Read more
Environmental regulation of Medical Devices (Canadian Environment Protection Act (CEPA), Chemicals Management Plan, provincial Stewardship regulations), Addressing issues and providing advice related to Medical Devices concerned by these regulations and participation in legislative/regulatory processes with the intent of seeking reasonable approaches based on scientific evidence and revising policies where needed.
Advancing the recommendations made by the Health & Biosciences Economic Strategy Table to grow the medical technology industry in Canada.
-
Reported by Nicole DeKort · In-house (organization)
- Jason Easton · Strategic Advisor Special Projects, Prime Minister's Office (PMO)
- Stephanie Di Tripani · Director, Health Canada (HC)
Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada. Read more
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.
-
Reported by Nicole DeKort · In-house (organization)
- Dominic LeBlanc · Minister of Finance, Finance Canada (FIN)
- Aaron Fowler · Deputy chief trade commissioner, Global Affairs Canada (GAC)
- Mark Holland · Minister of Health, Health Canada (HC)
Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada. Read more
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.
-
Reported by Nicole DeKort · In-house (organization)
- Jonathan Alomoto · Senior Policy Advisor, Global Affairs Canada (GAC)
Innovation, Science and Economic Development Canada - advocating that the federal government work across all government relevant Ministries and with key stakeholders to advance the adoption of novel and innovative health innovations and grow the medical technology industry in Canada including forming a permanent cross ministerial and stakeholder collaborative roundtable/advisory group. Advocating for the development of a commercialization framework and adoption of medical technologies & health innovations strategy in Canada. Read more
Discussions re. Policies to incent global medical technology companies to invest their R&D dollars in Canada, changes to the Scientific Research and Experimental Development tax credit and the impact on medical technology companies in Canada, the adoption of a common national framework to measuring health outcomes resulting in greater efficiencies and lower costs.
-
Reported by Nicole DeKort · In-house (organization)
- Bruce Randall · Director General, Health Canada (HC)
HealthIndustry
-
Reported by Nicole DeKort · In-house (organization)
- David Boudreau · Executive Director, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- David Boudreau · Executive Director, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- Ed Morgan · Director General, Health Canada (HC)
- David Lee · Chief Regulatory Officer, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- David Boudreau · Executive Director, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- Han Dong · Member of Parliament, House of Commons
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- Michael Collins · Director General, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- Zoe Hawa · Deputy Director, Global Affairs Canada (GAC)
Economic DevelopmentHealthIndustryInternational TradeScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- David Boudreau · Executive Director, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- David Boudreau · Executive Director, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- Michael Collins · Director General, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- David Boudreau · Executive Director, Health Canada (HC)
Industry
-
Reported by Nicole DeKort · In-house (organization)
- Wilson Maio · Member of Parliament, House of Commons
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- David Boudreau · Executive Director, Health Canada (HC)
Health
-
Reported by Nicole DeKort · In-house (organization)
- Michael Collins · Director General, Health Canada (HC)
- Matthew Jones · Federal Lead Covid-19 Testing Secretariat, Health Canada (HC)
HealthIndustryScience and Technology
-
Reported by Nicole DeKort · In-house (organization)
- Nancy Hamzawi · Assistant Deputy Minister, Health Canada (HC)
HealthIndustryScience and Technology
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.